Skip to main content

PARCKA/GIN Study Endorsed

PARCKA/GIN Study Endorsed for Enrollment

The Program for Addiction Research, Clinical Care, Knowledge, and Advocacy (PARCKA) and the Greater Intermountain Node (GIN) are pleased to announce that the Emergency Department-INitiated BupreNOrphine VAlidaTIOn Network Trial (CTN 0099) has been endorsed to begin enrollment.

This study will recruit, train and provide resources to 30 Emergency Department (ED) sites throughout the U.S. to implement ED-initiated buprenorphine (BUP) for patients presenting with untreated opioid use disorder (OUD).  A pragmatic randomized clinical trial (RCT) comparing the effectiveness of sublingual buprenorphine (SL-BUP) versus a 7-day extended-release formulation of buprenorphine (XR-BUP) in 2000 patients with untreated OUD will be conducted in sites achieving competence (e.g. demonstrating ability to enroll patients with OUD and adhere to protocols for administering both formulations of buprenorphine). The primary outcome will be engagement in formal addiction treatment within 7-days post ED visit. Engagement in formal addiction treatment on the 30th day post randomization and cost effectiveness will also be studied.

Learn more about PARCKA's research here.